Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shawn G. Kwatra, Peter Lio, Stephan Weidinger, Brian Calimlim, Barry Ladizinski, Namita Vigna, Willings Botha & Carol Mansfield. (2023) Patient preferences for atopic dermatitis treatments: a discrete choice experiment. Journal of Dermatological Treatment 34:1.
Read now
Read now
Kelley Myers, Jonathan I. Silverberg, Shreekant Parasuraman, Anna Pierce, Lawrence F. Eichenfield & Christine Poulos. (2023) Treatment preferences among patients with mild-to-moderate atopic dermatitis. Journal of Dermatological Treatment 34:1.
Read now
Read now
Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo & Michael C. Cameron. (2022) Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. Journal of Dermatological Treatment 33:5, pages 2605-2613.
Read now
Read now
Claire Ervin, Rebecca Crawford, Emily Evans, Steven R. Feldman, Joshua Zeichner, Michael A. Zielinski, Joseph C. Cappelleri, Marco DiBonaventura, Liza Takiya & Daniela E. Myers. (2022) Patient and caregiver preferences on treatment attributes for atopic dermatitis. Journal of Dermatological Treatment 33:4, pages 2225-2233.
Read now
Read now
Articles from other publishers (11)
Andrew Blauvelt, Richard G. Langley, Kenneth B. Gordon, Jonathan I. Silverberg, Kilian Eyerich, Morten O. A. Sommer, Jakob Felding & Richard B. Warren. (2023) Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review. Dermatology and Therapy 13:12, pages 3031-3042.
Crossref
Crossref
Alicja Mesjasz, Karol Kołkowski, Andreas Wollenberg & Magdalena Trzeciak. (2023) How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?. International Journal of Molecular Sciences 24:8, pages 7557.
Crossref
Crossref
Damon Willems, Eva-Lotta Hinzpeter, Hessel H. Van der Zee, Christopher J. Sayed, John R. Ingram, Charlotte Beaudart, Silvia M. A. A. Evers & Mickael Hiligsmann. (2023) Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe. The Patient - Patient-Centered Outcomes Research 16:2, pages 153-164.
Crossref
Crossref
Keon Andre Maleki-Yazdi, Anja Fog Heen, Irene X. Zhao, Gordon H. Guyatt, Erica A. Suzumura, Nima Makhdami, Lina Chen, Tonya Winders, Kathryn E. Wheeler, Julie Wang, Jonathan Spergel, Jonathan I. Silverberg, Peck Y. Ong, Monica O’Brien, Stephen A. Martin, Peter A. Lio, Mary Laura Lind, Jennifer LeBovidge, Elaine Kim, Joey Huynh, Matthew Greenhawt, Winfred T. Frazier, Kathy Ellison, Korey Capozza, Anna De Benedetto, Mark Boguniewicz, Wendy Smith Begolka, Rachel Netahe Asiniwasis, Lynda C. Schneider & Derek K. Chu. (2023) Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema). JAMA Dermatology 159:3, pages 320.
Crossref
Crossref
Jonathan I. Silverberg, Robert Bissonnette, Leon Kircik, Dedee F. Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia & Emma Guttman‐Yassky. (2023)
Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis (
ADVISE
)
. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Erica N. Browne, Kgahlisho Manenzhe, Wanzirai Makoni, Sikhanyisiwe Nkomo, Imelda Mahaka, Khatija Ahmed, Mary Kate Shapley-Quinn, Tozoe Marton, Ellen Luecke, Leah Johnson, Ariane van der Straten & Alexandra M. Minnis. (2023) Incorporating end-users’ voices into the development of an implant for HIV prevention: a discrete choice experiment in South Africa and Zimbabwe. BMC Women's Health 23:1.
Crossref
Crossref
Caitlin Thomas, Afaf Raibouaa, Andreas Wollenberg, Jean-Philippe Capron, Nicolas Krucien, Hayley Karn & Tommi Tervonen. (2022) Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment. BMJ Open 12:8, pages e058799.
Crossref
Crossref
Kristian Reich, Jacob P Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P Rice, H Chih-ho Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez & Urs Kerkmann. (2022) Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. The Lancet 400:10348, pages 273-282.
Crossref
Crossref
José Manuel Carrascosa Carrillo, Eulalia Baselga Torres, Yolanda Gilaberte Calzada, Yanina Nancy Jurgens Martínez, Gastón Roustan Gullón, Juan Ignacio Yanguas Bayona, Susana Gómez Castro, Maria Giovanna Ferrario & Francisco José Rebollo Laserna. (2022) Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment. Dermatology and Therapy 12:5, pages 1197-1210.
Crossref
Crossref
J.P. Thyssen, G. Yosipovitch, C. Paul, S.G. Kwatra, C.‐Y. Chu, M. DiBonaventura, C. Feeney, F. Zhang, D. Myers, R. Rojo & H. Valdez. (2021) Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology 36:3, pages 434-443.
Crossref
Crossref
J. Gutermuth, A.E. Pink, M. Worm, L. Soldbro, C. Bjerregård Øland & S. Weidinger. (2021) Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial (ECZTRA 7)*. British Journal of Dermatology 186:3, pages 440-452.
Crossref
Crossref